Sinoway Industrial Co.LTD.

Pimobendan

• Category :

  Pharmaceuticals and Biochemicals

• Synonyms :

  (��)-UD CG 115BS;2-(4-methoxyphenyl)-5(6)-(5-methyl-3-oxo-4,5-dihydro-2H-6-pyridazinyl)benzimidazole;3(2H)-pyridazinone, 4,5-dihydro-6-[2-(4-methoxyphenyl)-1H-benzimidazol-5-yl]-5-methyl-;3(2H)-pyridazinone, 4,5-dihydro-6-[2-(4-methoxyphenyl)-1H-benzimidazol-6-yl]-5-methyl-;4,5-Dihydro-6-[2-(4-methoxyphenyl)-1H-benzimidazol-5-yl]-5-methyl-3(2H)-pyridazinone;6-[2-(4-Methoxyphenyl)-1H-benzimidazol-5-yl]-5-methyl-4,5-dihydropyridazin-3(2H)-one;6-[2-(4-Methoxyphenyl)-1H-benzimidazol-6-yl]-5-methyl-4,5-dihydropyridazin-3(2H)-one;UD CG 115 BS;pimobenda;

• CAS NO :

  74150-27-9

• EC NO :

• Molecular Formula :

  C₁₉H₁₈N₄O₂

• Molecular Weight :

  334.37

• Main Specifications :

  99% up

• InChI :

  InChI=1/C19H18N4O2/c1-11-9-16(22-23-19(11)24)13-5-8-15-17(10-13)21-18(20-15)12-3-6-14(25-2)7-4-12/h3-8,10-11H,9H2,1-2H3,(H,20,21)(H,23,24)/t11-/m1/s1

• Packing :

  1kg/bag, 5kg/bag, or as per customers’ requirements.

• Product description :

  Pimobendan is a veterinary medication. It is a calcium sensitizer and a selective inhibitor of phosphodiesterase 3 (PDE3) with positive inotropic and vasodilator effects. Pimobendan is used in the management of heart failure in dogs, most commonly caused by myxomatous mitral valve disease (also previously known as endocardiosis), or dilated cardiomyopathy. Research has shown that as a monotherapy, pimobendan increases survival time and improves quality of life in canine patients with congestive heart failure secondary to mitral valve disease when compared with benazepril, an ACE inhibitor. However, in clinical practice, it is often used in conjunction with an ACE inhibitor like enalapril or benazepril.

• Uses :

  Dogs Congestive Heart Failure

• Molecular Structure :